MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cam4.71496

Медицинская библиотека · Cancer medicine · 2026

Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122.

Chan Anthony T C, Lee Victor Ho Fun, Hong Ruey-Long, Ahn Myung-Ju, Chong Wan Qin, Spreafico Anna, Kim Sung-Bae, Ho Gwo Fuang, Caguioa Priscilla B, Ngamphaiboon Nuttapong, Swaby Ramona F, Wei Bo, Webber Andrea L, Kang John, Gumuscu Burak, Yuan Jianda, Siu Lillian L

СтатьяРандомизированное исследованиеКлиническое исследование III фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Plasma Epstein-Barr virus (EBV) DNA has clinical utility for prognosis, recurrence, surveillance, and treatment response in nasopharyngeal carcinoma (NPC). This exploratory analysis evaluated associations between plasma EBV DNA load and clinical outcomes in participants treated with pembrolizumab or chemotherapy in the phase 3 KEYNOTE-122 trial (NCT02611960).

METHODS

Participants with platinum-pretreated, histologically confirmed, EBV-positive, recurrent/metastatic NPC were randomly assigned (1:1) to pembrolizumab 200 mg intravenously every 3 weeks (≤ 35 cycles) or standard of care (SOC; investigator's choice of capecitabine, gemcitabine, or docetaxel). Associations between baseline plasma EBV DNA load as a continuous variable and plasma EBV DNA fold change at cycle 2 day 1 (C2D1), with clinical outcomes (progression-free survival [PFS], overall survival [OS], and objective response rate [ORR]) were evaluated within each treatment arm. Nominal significance was prespecified at 0.05 for 1-sided p values.

RESULTS

Of 228 treated participants, 215 (94.3%) had evaluable baseline plasma EBV DNA load data (pembrolizumab, 111; SOC, 104). Baseline plasma EBV DNA load was negatively associated with PFS and OS for pembrolizumab and SOC (both p < 0.005) but not ORR (p = 0.105, pembrolizumab; p = 0.473, SOC). Larger decreases in plasma EBV DNA load at C2D1 relative to baseline were associated with improved PFS, OS, and ORR for pembrolizumab and SOC (p ≤ 0.005).

CONCLUSIONS

Higher baseline plasma EBV DNA load was negatively associated with outcomes in participants with NPC treated with pembrolizumab or SOC. These findings provide additional support for plasma EBV DNA as a prognostic biomarker for NPC.

TRIAL REGISTRATION: ClinicalTrials.gov, NCT02611960.

Для цитирования: Chan Anthony T C, Lee Victor Ho Fun, Hong Ruey-Long, Ahn Myung-Ju, Chong Wan Qin, Spreafico Anna, Kim Sung-Bae, Ho Gwo Fuang, Caguioa Priscilla B, Ngamphaiboon Nuttapong, Swaby Ramona F, Wei Bo, Webber Andrea L, Kang John, Gumuscu Burak, Yuan Jianda, Siu Lillian L. Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122.. Cancer medicine. 2026. DOI: 10.1002/cam4.71496.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.